Examining sodium levels and administration in ICU patients

Plasma Sodium and Sodium Administration in the ICU. A Retrospective Observational Study.

This study looks at how ICU patients' sodium levels are managed with IV fluids and medications to see if current treatment practices are helping them recover better.

Quick facts

• Study type: Observational
• Enrollment: 200 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: University Hospital, Linkoeping (other)
• Locations: 1 site (Linköping)
• Trial ID: NCT06037928 on ClinicalTrials.gov

What this trial studies

This observational study focuses on patients in the Intensive Care Unit (ICU) who often experience abnormal plasma sodium levels, either too low (hyponatremia) or too high (hypernatremia). It aims to assess the administration of sodium through intravenous fluids and medications, questioning whether current practices are optimal and consistent among physicians. By analyzing the sodium levels and the corresponding treatment approaches, the study seeks to understand the impact of sodium management on patient outcomes in critical care settings.

Who should consider this trial

Good fit: Ideal candidates for this study are adults who have spent at least seven days in the ICU and have been discharged, with a BMI between 18.0 and 48.0 kg/m2.

Not a fit: Patients with severe sodium imbalances or those undergoing dialysis during the observation period may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved sodium management strategies in ICU patients, potentially enhancing their recovery and outcomes.

How similar studies have performed: While the approach of examining sodium administration in ICU settings is not widely tested, there is emerging interest in optimizing fluid therapy, suggesting potential for impactful findings.

Eligibility criteria

Inclusion Criteria:

* Adult
* Documented length of stay at the Central Intensive Care Unit (CIVA) at the University Hospital of Linköping of seven (7) days minimum.
* The patient has been discharged from the ICU.
* Body Mass Index (BMI) between 18.0 and 48.0 kg/m2 at admission.

Exclusion Criteria:

* The patient has previously been included in the study in connection with another ICU-admission.
* The patient has a severe hyponatremia (\<129 mmol/L) upon arrival to the ICU.
* The patient has a severe hypernatremia (\>149 mmol/L) upon arrival to the ICU.
* The patient is severely hyperosmolar (\>330 mmol/L) upon arrival to the ICU.
* The patient is severely hyperglycemic (\>30 mmol/L) upon arrival to the ICU.
* The patient has an elevated serum urea (\>30 mmol/L) upon arrival to the ICU.
* The patient receives any dialysis treatment during the observation time.
* The patient is suspected to have an elevated intracranial pressure during the observation time or is suspected to have other intracranial pathology that is likely to affect sodium homeostasis
* The patient has an intoxication with toxic alcohols as a primary diagnosis.

Where this trial is running

Linköping

• University Hospital Linköping — Linköping, Sweden (RECRUITING)

Study contacts

• Study coordinator: Hans Bahlmann, MD, PhD

Conditions: Hypernatremia, Hyponatremia, Critical Illness, Fluid Therapy, ICU, Drug Prescription